1 | Visilizumab | 1件: Visilizumab Visilizumab | 1件: D06314
D06314
(Name: Visilizumab) | 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 2件: 96 96, 97 |
2 | Visilizumab (HuM291 | 1件: Visilizumab Visilizumab | 1件: D06314
D06314
(Name: Visilizumab) | 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 97 97 |
3 | Visilizumab (Nuvion) | 1件: Visilizumab Visilizumab | 1件: D06314
D06314
(Name: Visilizumab) | 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 97 97 |
4 | Visilizumab (Nuvion® | 1件: Visilizumab Visilizumab | 1件: D06314
D06314
(Name: Visilizumab) | 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 97 97 |